GeneHealth - Your precision medicine

Patent Ductus Arteriosus

Disease Details

Family Health Simplified

Buy Membership

Description: Patent ductus arteriosus is a heart defect where the ductus arteriosus, a blood vessel that allows blood to bypass the lungs in fetal circulation, fails to close after birth, leading to abnormal blood flow between the aorta and pulmonary artery.
Type: Patent ductus arteriosus (PDA) is primarily a congenital heart defect. It is not typically classified under a specific type of genetic transmission, as it can result from a combination of genetic and environmental factors. However, there are rare instances where PDA can be associated with genetic syndromes or inherited in a multifactorial manner, involving contributions from multiple genes and possibly environmental influences.
Signs And Symptoms: Common symptoms include:
dyspnea (shortness of breath)Signs include:
tachycardia (a heart rate exceeding the normal resting rate)
continuous "machine-like" (also described as "rolling-thunder" and "to-and-fro") heart murmur (usually from aorta to pulmonary artery, with higher flow during systole and lower flow during diastole)
cardiomegaly (enlarged heart, reflecting ventricular dilation and volume overload)
left subclavicular thrill
bounding pulse
widened pulse pressure
increased cardiac output
increased systolic pressure
poor growth
differential cyanosis, i.e. cyanosis of the lower extremities but not of the upper body.People with patent ductus arteriosus typically present in good health, with normal respirations and heart rate. If the PDA is moderate or large, widened pulse pressure and bounding peripheral pulses are frequently present, reflecting increased left ventricular stroke volume and diastolic run-off of blood into the (initially lower-resistance) pulmonary vascular bed. Eisenmenger physiology is pulmonary hypertension due to a left-to-right shunt. Prominent suprasternal and carotid pulsations may be noted secondary to increased left ventricular stroke volume.
Prognosis: If left untreated, the disease may progress from left-to-right shunt (acyanotic heart) to right-to-left shunt (cyanotic heart), called Eisenmenger's syndrome. Pulmonary hypertension is a potential long-term outcome, which may require a heart and/or lung transplant. Another complication of PDA is intraventricular hemorrhage.
Onset: Patent ductus arteriosus (PDA) typically presents at birth or in the neonatal period, especially in premature infants. It occurs when the ductus arteriosus, a fetal blood vessel that bypasses pulmonary circulation, fails to close after birth.
Prevalence: The prevalence of patent ductus arteriosus (PDA) varies depending on the population. In full-term infants, PDA occurs in approximately 1 in 2,000 live births. However, the incidence is significantly higher in premature infants, particularly those born before 28 weeks of gestation, with rates ranging from 20% to 60%.
Epidemiology: Patent ductus arteriosus (PDA) is a congenital heart defect where the ductus arteriosus fails to close after birth. The epidemiology of PDA includes:

1. **Incidence:** PDA is more common in premature infants, with an incidence ranging from 20-60% in preterm neonates. In full-term infants, the incidence is around 1 in 2,000 live births.

2. **Gender Differences:** PDA is more frequently observed in females than in males, with a female-to-male ratio of approximately 2:1.

3. **Geographical Variability:** The incidence of PDA can vary based on geographical location and ethnicity, although detailed statistics may differ.

4. **Risk Factors:**
- Prematurity and low birth weight are significant risk factors.
- Genetic conditions such as Down syndrome increase the likelihood of PDA.
- Maternal factors like rubella infection during pregnancy can also elevate the risk.

5. **Associated Conditions:** PDA often coexists with other congenital heart defects.

Monitoring and early detection via echocardiography are crucial for managing the condition effectively, especially in at-risk populations.
Intractability: Patent ductus arteriosus (PDA) is not typically intractable. It is a congenital heart defect where the ductus arteriosus fails to close after birth. Treatment options, including medications, catheter-based procedures, or surgery, are generally effective in closing the ductus arteriosus and managing symptoms, leading to a good prognosis in most cases.
Disease Severity: Patent ductus arteriosus (PDA) is a heart condition in which the ductus arteriosus, a blood vessel in a baby's heart that normally closes after birth, remains open. The severity of PDA can vary:

- **Mild**: May be asymptomatic and discovered incidentally; often closes on its own.
- **Moderate**: Can cause symptoms such as breathlessness, poor feeding, and slow growth; may require medical management.
- **Severe**: Can lead to heart failure, pulmonary hypertension, or other serious complications; often necessitates surgical intervention.

In neonatal medicine, a timely diagnosis and appropriate management based on severity are crucial.
Healthcare Professionals: Disease Ontology ID - DOID:13832
Pathophysiology: Patent ductus arteriosus (PDA) is a condition where the ductus arteriosus, a fetal blood vessel that connects the pulmonary artery to the aorta, fails to close after birth. Normally, this vessel closes spontaneously shortly after birth as the neonate's circulatory system adjusts to breathing air. In PDA, this closure does not occur, leading to abnormal blood flow between the aorta and the pulmonary artery.

Pathophysiology:
In PDA, the persistence of the ductus arteriosus allows oxygenated blood from the aorta to mix with deoxygenated blood in the pulmonary artery due to the higher pressure in the aorta. This results in increased blood flow to the lungs. The increased pulmonary circulation can lead to pulmonary congestion and reduced systemic blood flow. Over time, this may cause complications such as pulmonary hypertension, heart failure, and an increased risk of bacterial endocarditis. The heart has to work harder to pump the increased volume of blood, potentially leading to left ventricular hypertrophy and heart failure if untreated.
Carrier Status: Patent ductus arteriosus (PDA) is a congenital heart defect rather than a condition associated with carrier status. It occurs when the ductus arteriosus, a blood vessel in a baby's heart, fails to close after birth. This can lead to abnormal blood flow between the aorta and the pulmonary artery. Genetic factors can play a role, but PDA itself is not inherited in a manner that would involve carrier status.
Mechanism: Patent ductus arteriosus (PDA) is a condition where the ductus arteriosus, a blood vessel in a developing fetus, fails to close after birth. Normally, this vessel allows blood to bypass the lungs in fetal circulation but closes soon after birth to ensure proper blood flow through the lungs.

### Mechanism:
In PDA, the persistent patency of the ductus arteriosus leads to abnormal blood flow between the aorta and the pulmonary artery. This can result in various complications, including increased workload on the heart and increased blood flow to the lungs, potentially leading to heart failure and other issues.

### Molecular Mechanisms:
1. **Prostaglandins:**
- Prostaglandins, particularly Prostaglandin E2 (PGE2), play a crucial role in keeping the ductus arteriosus open during fetal development. Elevated levels of PGE2 help maintain the patency of this vessel.
- After birth, a decrease in PGE2 levels typically results in the constriction and closure of the ductus arteriosus. In PDA, this decrease may not occur effectively.

2. **Oxygen:**
- Increased oxygen tension after birth usually leads to the constriction of the ductus arteriosus. Delays or insufficiencies in this oxygen-mediated response can contribute to PDA.

3. **Genetic Factors:**
- Genetic predispositions can also influence the behavior of the ductus arteriosus. Mutations or variations in genes involved in vascular development and response to oxygen and prostaglandins can affect the closure process.

4. **Smooth Muscle Cell Function:**
- The smooth muscle cells in the ductus arteriosus play a pivotal role in its closure. Any abnormalities in the contractility or apoptosis (programmed cell death) of these cells can result in PDA.

Understanding the molecular mechanisms helps in developing specific targeted therapies aimed at promoting closure of the ductus arteriosus or managing complications associated with PDA.
Treatment: Symptomatic PDA can be treated with both surgical and non-surgical methods.
Compassionate Use Treatment: Patent Ductus Arteriosus (PDA) is a heart condition often treated with both standard and experimental approaches, particularly in cases where conventional methods are insufficient.

1. **Compassionate Use Treatment**:
- Compassionate use, also known as expanded access, allows patients to access investigational treatments outside clinical trials. For PDA, this could include novel medical devices or drugs under development that are not yet fully approved.

2. **Off-label Treatments**:
- **Indomethacin or Ibuprofen**: These medications, commonly used for other purposes such as pain relief, are often administered off-label to help close the ductus arteriosus in preterm infants.
- **Acetaminophen (Paracetamol)**: Though mainly used for pain and fever, it has been investigated off-label for PDA due to its potential efficacy in closing the ductus.

3. **Experimental Treatments**:
- **Transcatheter Device Closure**: Newer devices and techniques are constantly being studied to improve the safety and efficacy of non-surgical PDA closures in infants and children.
- **Gene Therapy**: Still in the very early stages, research is being conducted to explore the potential for gene therapy to address the underlying causes of PDA.

These approaches can offer hope for PDA patients, particularly when traditional treatments are not suitable or have failed.
Lifestyle Recommendations: For patients with patent ductus arteriosus (PDA), lifestyle recommendations may vary depending on the severity of the condition and whether it has been treated. However, some general guidelines include:

1. **Regular Check-ups**: Continual monitoring by a healthcare provider is essential to track the condition and manage any complications.

2. **Healthy Diet**: A balanced diet rich in fruits, vegetables, whole grains, and lean proteins can help maintain overall cardiovascular health.

3. **Physical Activity**: Engage in moderate physical activities, but consult with a healthcare provider on appropriate levels of exercise, especially if symptoms like shortness of breath are present.

4. **Avoid Infections**: Flu and other infections can be more risky for those with PDA. Vaccinations and good hygiene practices can help prevent illness.

5. **Medication Adherence**: If prescribed, ensure regular intake of medications like NSAIDs to help close the PDA or other medications for symptom management.

6. **Stress Management**: Practice stress-reducing techniques such as yoga, meditation, or breathing exercises to maintain emotional and physical well-being.

7. **Avoid Smoking and Alcohol**: Both smoking and excessive alcohol consumption can exacerbate heart issues and should be avoided.

Each individual's situation is unique, so it is important to follow personalized advice from healthcare professionals.
Medication: Patent ductus arteriosus (PDA) can sometimes be treated with medications, particularly in premature infants. The primary medications used are:

1. **Indomethacin**: A nonsteroidal anti-inflammatory drug (NSAID) that helps close the ductus arteriosus by inhibiting prostaglandin synthesis.
2. **Ibuprofen**: Another NSAID that similarly works by reducing prostaglandin levels to promote closure of the ductus arteriosus.

Both medications are commonly administered intravenously and are more effective when used in the first few weeks after birth.
Repurposable Drugs: There are several drugs that can be repurposed for treating patent ductus arteriosus (PDA), especially in preterm infants. The most commonly used medications include:

1. **Indomethacin**: A nonsteroidal anti-inflammatory drug (NSAID) that helps close the ductus arteriosus by inhibiting prostaglandin synthesis.
2. **Ibuprofen**: Another NSAID that can be used similarly to indomethacin to encourage ductus arteriosus closure.
3. **Acetaminophen (Paracetamol)**: Has been found to be an effective alternative in closing PDA, especially for infants who do not respond to or cannot tolerate NSAIDs.

These medications aim to induce closure by reducing the levels of prostaglandins, which help keep the ductus arteriosus open.
Metabolites: Patent ductus arteriosus (PDA) is not primarily characterized by specific metabolites that serve as biomarkers for the condition. Instead, PDA is a congenital heart defect that involves the persistence of the ductus arteriosus, a fetal blood vessel that normally closes shortly after birth. The focus of diagnosis and treatment typically involves imaging techniques like echocardiography and interventions to close the ductus arteriosus if necessary. Certain markers of cardiac function and heart strain might be monitored, but there are no specific metabolites unique to PDA diagnosis and management.
Nutraceuticals: There are no specific nutraceuticals that have been proven to treat or manage patent ductus arteriosus (PDA). Treatment typically involves medical management with non-steroidal anti-inflammatory drugs (NSAIDs) like indomethacin or ibuprofen, or surgical intervention if necessary. Always consult with a healthcare professional for appropriate treatment options.
Peptides: Patent ductus arteriosus (PDA) is a congenital heart condition characterized by the persistence of the ductus arteriosus, a fetal blood vessel that normally closes after birth. In PDA, this vessel remains open, allowing blood to flow abnormally between the aorta and the pulmonary artery.

The term "peptides, nan" isn’t commonly associated with standard clinical descriptions of PDA. If you are inquiring about specific peptide treatments or nanotechnology applications related to PDA, please note that current primary treatments include pharmacological interventions (such as NSAIDs like ibuprofen or indomethacin), catheter-based procedures, and surgical interventions, rather than peptide or nanotechnology-based treatments.

However, research in these advanced fields is ongoing, and these innovative approaches could provide potential future treatments.